No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina / NY / Florida       

Synexa Life Sciences Expands Biomarker Discovery Capabilities with the Addition of Olink® Target Platform

What To Know

  • Synexa Life Sciences, a global Clinical Laboratory Services provider for the biopharma industry, announces the integration of the Olink® Target immunoassays and the Olink® Signature Q100 instrument into its extensive suite of biomarker discovery platforms.
  • The Olink Signature Q100 is a purpose-built benchtop system designed to meet the exact demands of clinical laboratory services in the pharmaceutical, biotech, and contract research organization (CRO) sectors.

Synexa Life Sciences

Synexa Life Sciences, a global Clinical Laboratory Services provider for the biopharma industry, announces the integration of the Olink® Target immunoassays and the Olink® Signature Q100 instrument into its extensive suite of biomarker discovery platforms.

The adoption of Olink Signature Q100 represents a significant step forward in Synexa’s commitment to providing leading biomarker and bioanalytical solutions to its pharma and biotech customers. Olink Signature Q100 processes and analyses Olink Target assays in the format of disease focused panels that require as little as 1 μL of serum, plasma, or other biological sample types. Profiled protein biomarkers reveal deeper insights into disease mechanisms, identifying potential therapeutic targets, and accelerating the development of innovative treatments.

Justin Devine, Chief Innovation Officer

“By adding the Olink platform into our service line, Synexa can further support researchers’ efforts in several key areas including translational research, patient centric sampling and extracellular vesicle analysis.”

Emile Lens, CEO at Synexa Life Sciences stated:

“The addition of Olink to the Synexa technology portfolio demonstrates our continued commitment to strengthening our biomarker and bioanalysis capabilities across several expertise areas including oncology, immuno-oncology, infectious diseases and more. Incorporating Olink into our service portfolio allows us to solve clinical research questions more effectively, greatly expanding access to proteomics for deeper biological insights to our global customers.”

The Olink Signature Q100 is a purpose-built benchtop system designed to meet the exact demands of clinical laboratory services in the pharmaceutical, biotech, and contract research organization (CRO) sectors. It offers a wide array of capabilities, including high-throughput multiplex protein biomarker measurement and data analysis, utilizing a seamless workflow saving time at the lab bench. This allows researchers to efficiently process vast samples and datasets and accelerate drug discovery and enhance personalized medicine.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More

Advertise wiith Medical Device News Magazine

By using this website you agree to accept Medical Device News Magazine Privacy Policy